Analysis of promoter non-CG methylation in prostate cancer

Matthew Truong, Bing Yang, Jennifer Wagner, Joshua Desotelle, David F. Jarrard

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background: In vertebrates, DNA methylation occurs primarily at CG dinucleotides but recently, non-CG methylation has been found at appreciable levels in embryonic stem cells. Materials & methods: To assess non-CG methylation in cancer, we compared the extent of non-CG methylation at several biologically important CG islands in prostate cancer and normal cell lines. An assessment of the promoter CG islands EVX1 and FILIP1L demonstrates a fourfold higher rate of non-CG methylation at EVX1 compared with FILIP1L across all cell lines. These loci are densely methylated at CG sites in cancer. Results: No significant difference in non-CG methylation was demonstrated between cancer and normal. Treatment of cancer cell lines with 5-azacytidine significantly reduced methylation within EVX1 at CG and CC sites, preferentially. Conclusion: Non-CG methylation does not correlate with CG methylation at hypermethylated promoter regions in cancer. Furthermore, global inhibition of DNA methyltransferases does not affect all methylated cytosines uniformly.

Original languageEnglish (US)
Pages (from-to)65-71
Number of pages7
Issue number1
StatePublished - Feb 2013
Externally publishedYes


  • 5-azacytidine
  • EVX1
  • epigenetics
  • non-CG methylation
  • prostate cancer

ASJC Scopus subject areas

  • Genetics
  • Cancer Research


Dive into the research topics of 'Analysis of promoter non-CG methylation in prostate cancer'. Together they form a unique fingerprint.

Cite this